Biochemistry · Retroviruses & HIV
Human Immunodeficiency Virus (HIV) is a retrovirus belonging to the Lentivirus genus, characterized by its ability to integrate into the host genome and establish chronic infection. Retroviruses are enveloped, single-stranded RNA viruses that utilize reverse transcriptase to convert their RNA genome into double-stranded DNA, a defining feature of their replication cycle. HIV primarily targets CD4+ T lymphocytes, leading to progressive immune system dysfunction and acquired immunodeficiency syndrome (AIDS) if untreated.
Detection of HIV relies on understanding its molecular biology, including viral structure, replication mechanisms, and host interactions. Biochemical assays target viral components such as RNA, proteins (e.g., p24 antigen), or host antibodies generated in response to infection. These methods form the basis of diagnostic testing, monitoring, and research into antiviral therapies.
The HIV genome consists of two identical single-stranded RNA molecules enclosed within a nucleocapsid. Upon entry into the host cell, viral reverse transcriptase synthesizes a complementary DNA (cDNA) strand from the RNA template, followed by degradation of the RNA strand via RNase H activity. The resulting single-stranded DNA is then used as a template to generate double-stranded DNA, which integrates into the host genome via the viral integrase enzyme. This process is error-prone, contributing to high mutation rates and viral diversity.
HIV encodes structural, enzymatic, and regulatory proteins critical for its life cycle. The gag gene produces structural proteins such as p24 (capsid), p17 (matrix), and p7 (nucleocapsid), which assemble into the viral core. The pol gene encodes essential enzymes, including reverse transcriptase, integrase, and protease, which are targets for antiretroviral therapy. The env gene encodes envelope glycoproteins gp120 and gp41, which mediate viral entry by binding to CD4 and co-receptors (CCR5 or CXCR4) on host cells.
HIV detection methods are categorized into direct and indirect assays. Direct methods identify viral components, such as RNA (via nucleic acid amplification tests, e.g., PCR) or p24 antigen (via enzyme-linked immunosorbent assay, ELISA). Indirect methods detect host antibodies against HIV, typically using ELISA or Western blot for confirmation. Fourth-generation assays combine antigen and antibody detection to reduce the diagnostic window period, improving early detection sensitivity.
Reverse transcriptase (RT) is a key target for both diagnostic and therapeutic strategies. RT activity assays measure the enzyme's ability to synthesize DNA from an RNA template, providing a functional readout of viral replication. These assays are used in research and clinical settings to monitor viral load and assess drug resistance. Nucleoside and non-nucleoside RT inhibitors (NRTIs and NNRTIs) exploit the enzyme's mechanism, blocking viral replication and forming the backbone of antiretroviral therapy.
Following HIV infection, the host immune system mounts a humoral response, producing antibodies against viral proteins. Seroconversion, the point at which antibodies become detectable, typically occurs 2-8 weeks post-exposure. The timing of seroconversion influences the diagnostic window period, during which direct viral detection methods (e.g., RNA or p24 antigen tests) are critical. Understanding the kinetics of antibody production is essential for interpreting diagnostic test results and guiding clinical management.
HIV is a retrovirus that relies on reverse transcriptase to convert its RNA genome into DNA for integration into the host genome. Its structural and enzymatic proteins, such as p24, gp120, and reverse transcriptase, are critical for viral replication and serve as targets for detection and therapy. Understanding the molecular biology of HIV is essential for developing and interpreting diagnostic assays, including nucleic acid tests, antigen detection, and antibody-based methods.
Early and accurate detection of HIV is crucial for initiating antiretroviral therapy, reducing transmission, and improving patient outcomes. Fourth-generation assays, which detect both p24 antigen and antibodies, have significantly shortened the diagnostic window period. Clinicians must interpret test results in the context of seroconversion kinetics and potential exposure history to ensure timely diagnosis and intervention.
Reverse transcriptase inhibitors, integrase inhibitors, and protease inhibitors form the cornerstone of antiretroviral therapy, targeting key steps in the HIV life cycle. Resistance to these drugs can emerge due to the high mutation rate of reverse transcriptase, necessitating regular viral load monitoring and genotypic resistance testing. Advances in biochemical understanding of HIV continue to drive the development of novel therapeutics and diagnostic tools.